Lead Product(s) : Ciprofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Savara
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Savara Obtains Global Rights to Develop and Commercialize Apulmiq
Details : Under the terms of the agreement, Savara has obtained the worldwide rights to develop and commercialize Apulmiq.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 04, 2020
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Savara
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Alpha1-proteinase Inhibitor
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Prolastin-C
Product Type : Protein
Upfront Cash : Inapplicable
November 13, 2013
Lead Product(s) : Alpha1-proteinase Inhibitor
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : STx-02
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Unidad de Investigacion Medica en Epidemiologia Clinica
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Evaluation in Recurrent Wheezing Attacks
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 28, 2012
Lead Product(s) : STx-02
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Unidad de Investigacion Medica en Epidemiologia Clinica
Deal Size : Inapplicable
Deal Type : Inapplicable